Last reviewed · How we verify
PJ009
PJ009 is a monoclonal antibody targeting PD-1.
PJ009 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | PJ009 |
|---|---|
| Also known as | Glucagon-like Peptide-2 (GLP-2) analogue, Glucagon-Like Peptide 2 (GLP-2) analogue, GLP-2 analogue Placebo |
| Sponsor | Chongqing Peg-Bio Biopharm Co., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PJ009 works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells and thereby enhancing T cell-mediated anti-tumor responses.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
Key clinical trials
- Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition (PHASE3)
- A Study of PJ009 in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PJ009 CI brief — competitive landscape report
- PJ009 updates RSS · CI watch RSS
- Chongqing Peg-Bio Biopharm Co., Ltd. portfolio CI